Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.
Menu

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference GlobeNewswire - Thu Aug 27, 8:01AM CDT

Video webcast now available  here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug...

AKTX : 10.40 (+0.29%)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire - Thu Aug 27, 8:01AM CDT

Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?

AKTX : 10.40 (+0.29%)
ERNA : 4.43 (+1.83%)
OTLK : 0.6208 (-0.37%)
AIM : 0.2352 (-0.34%)
CNSP : 5.91 (+0.30%)
NVNO : 10.98 (-4.27%)
DARE : 0.7728 (+0.34%)
GRI : 1.9498 (+2.08%)
MBRX : 0.6901 (+6.17%)
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference GlobeNewswire - Thu Aug 27, 8:01AM CDT

Video webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology...

AKTX : 10.40 (+0.29%)
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference ACN Newswire - Mon Aug 24, 10:59AM CDT

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.18 (+1.37%)
SER : 2.51 (+0.26%)
GANX : 1.7850 (+0.85%)
BIOA : 9.60 (+0.84%)
OSTX : 1.6600 (unch)
VTVT : 32.67 (+2.25%)
MASS : 10.82 (+1.60%)
PYPD : 5.23 (-1.88%)
TKNO : 7.39 (+4.38%)
OVID : 2.80 (+1.45%)
MDCX : 0.2550 (+1.51%)
EQ : 2.23 (+1.10%)
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy GlobeNewswire - Tue Aug 18, 7:53AM CDT

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating...

AKTX : 10.40 (+0.29%)
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy GlobeNewswire - Tue Aug 18, 7:53AM CDT

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of...

AKTX : 10.40 (+0.29%)
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform GlobeNewswire - Thu Aug 13, 3:15PM CDT

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism...

AKTX : 10.40 (+0.29%)
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform GlobeNewswire - Thu Aug 13, 3:15PM CDT

AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027

AKTX : 10.40 (+0.29%)
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation GlobeNewswire - Tue Aug 4, 7:50AM CDT

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's...

AKTX : 10.40 (+0.29%)
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation GlobeNewswire - Tue Aug 4, 7:50AM CDT

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload...

AKTX : 10.40 (+0.29%)

Barchart Exclusives

1 Trade to Make Now as Inflation Fears Swirl in September Barchart - 39 minutes ago
December U.S. T-Bond futures present a selling opportunity on more price weakness. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.